Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 25–48 of 328
Additional Cover
NAD+ preservation through dual mechanisms—inhibiting its depletion and enhancing its synthesis—delays cellular senescence while promoting musculoskeletal regeneration. This addresses a central constraint in aging: the body's declining capacity to maintain energy production and tissue repair as NAD+ levels fall with time.
A Combination NAD+ Treatment Has Benefits for Mice
Researchers demonstrated that combining NAD+ precursor supplementation (NMN) with apigenin, a compound that reduces NAD+ degradation, restores muscle function and bone structure in aged mice. This dual-mechanism approach addresses both NAD+ availability and preservation, with relevance to human aging given prior clinical evidence for NAD+ precursors in metabolic and respiratory function.
Ribupatide achieves 12% weight loss with GLP-1/GIP dual action
Ribupatide, a dual GLP-1/GIP receptor agonist in development as both oral and injectable formulations, achieved 12.1% mean weight loss at optimal doses in Phase 2 trials, with 38.6% of participants reaching 15% weight loss. Safety profile aligns with established GLP-1 therapies, positioning this compound as a potential alternative in the growing class of weight-loss pharmaceuticals.
Abinopharm releases AbinoNutra® NMN white paper after FDA reinstatement and clinical evidence
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
Deal between Chrysea, nuBioAge brings spermidine to clinics
A partnership between Chrysea Labs and nuBioAge moves spermidine into clinician-guided care through healthcare practitioners and pharmacies, signaling a shift toward evidence-based delivery of longevity interventions within clinical frameworks rather than direct-to-consumer wellness channels. This approach addresses a critical gap: standardized formulations and practitioner guidance that enable reproducible outcomes.
Increasing Senolytic Effectiveness by Stressing Mitochondria
Mitochondrial stress emerges as a critical mechanism underlying senolytic effectiveness against senescent cells. This finding suggests that the therapeutic benefit of senolytics depends partly on their capacity to induce cellular energy stress, offering a framework for optimizing drug selection and combination strategies in senescence-targeted interventions.
Lilly’s orforglipron beats oral semaglutide in diabetes trial
Eli Lilly's orforglipron demonstrated superior blood sugar control (2.2% reduction vs. 1.4%) and weight loss (9.2% vs. 5.3%) compared to oral semaglutide in the ACHIEVE-3 trial of 1,698 adults with type 2 diabetes. The oral formulation's flexibility—taken with meals rather than on an empty stomach—addresses a significant barrier to treatment adherence, though gastrointestinal side effects occurred in approximately 60% of patients.
Research links GLP-1s to osteoporosis and gout risks
GLP-1 medications are associated with a 30% relative increase in osteoporosis risk and modest increases in gout and bone softening, likely driven by rapid weight loss reducing skeletal load and potential nutritional deficiencies. These findings do not negate the drugs' metabolic benefits but require integrated monitoring and support strategies during treatment.
CagriSema and retatrutide signal the next GLP-1 arms race
Triple and dual agonist drugs like retatrutide and CagriSema target multiple metabolic pathways simultaneously, producing weight loss exceeding 20-30% in clinical trials. These medications represent a shift toward precision metabolic intervention, with implications for both obesity management and aging-related cellular stress.
Double‐Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration
A combination of NMN and apigenin preserves NAD+ levels, activating SIRT3 to suppress cellular senescence and promote differentiation of muscle, bone, and cartilage precursor cells. The regimen also modulates the gut microbiota to increase production of phytosphingosine, an anti-aging metabolite, resulting in improved musculoskeletal function and exercise capacity in aged animals.
Muscle-Sparing Weight Loss: Beyond GLP-1 Appetite Suppression
MetaShape's MS 001 candidate demonstrates potential to address GLP-1 therapy limitations by preserving muscle mass, deepening fat loss, and increasing energy expenditure in preclinical models. This shifts obesity treatment focus from total weight loss toward selective fat reduction while maintaining metabolic capacity.
Antag’s obesity drug targets fat storage, not appetite
AT7687, a GIP receptor antagonist, targets fat storage pathways rather than appetite suppression, demonstrating tolerability and early metabolic improvements in human trials. Combined with cagrilintide in preclinical studies, the compound achieved weight loss exceeding either drug alone while preserving lean mass and improving insulin sensitivity without increased gastrointestinal burden.
Early mitophagy activation by Urolithin A prevents, but late activation does not reverse, age-related cognitive impairment
Urolithin A activates mitophagy—the removal of damaged mitochondria—and prevents age-related cognitive decline when initiated early, but fails to reverse existing cognitive impairment when treatment begins after decline has already occurred. This temporal dependency defines a critical window for intervention in age-related neurodegeneration.
Antag Therapeutics to present AT7687 data at ADA 2026
Antag Therapeutics is advancing AT7687, a GIP receptor antagonist peptide, showing tolerability and weight loss potential in early human trials and demonstrating synergistic metabolic benefits when combined with cagrilintide in preclinical work. The compound represents a mechanistic approach to obesity and insulin resistance through peptide-based receptor antagonism rather than agonism.
RevGenetics unveils absorption-gap solution for berberine
RevGenetics has developed DiBerberine 300x, an enteric-coated supplement combining dihydroberberine with a proprietary flavonoid complex designed to overcome two primary absorption barriers: stomach acid degradation and P-glycoprotein efflux. The formulation reportedly achieves 6.7-fold greater plasma exposure compared to standard berberine at lower doses, addressing a long-standing bioavailability limitation that has constrained berberine's clinical utility.
Oral GLP-1 delivery matches injection outcomes in obesity treatment
Rani Therapeutics and PegBio are collaborating to develop oral formulations of obesity and metabolic disease therapeutics using Rani's RaniPill platform, a capsule-based delivery system. Preclinical data suggest oral delivery of GLP-1 agonists can achieve bioavailability and weight loss outcomes comparable to injectable formulations, addressing a significant barrier to patient adherence and treatment access.
Taurine Deficiency Triggers Aging Through Stem Cell Collapse
Cold-induced sexual differentiation in Hydra oligactis produces distinct metabolic signatures of both reproductive maturation and aging, with taurine depletion emerging as a critical marker of cellular decline. Taurine supplementation partially restored stem cell populations and shifted reproduction from sexual to asexual, suggesting a metabolic lever for longevity intervention.
Oral GLP-1 Pill Matches Injectable Results, Expands Treatment Access
Kailera's oral GLP-1 candidate HRS-7535 demonstrated 11.1% weight loss and meaningful improvements in glucose control and cardiovascular markers in Phase 3 trials. The significance lies not in efficacy alone, but in whether oral formulation can address the supply chain and access constraints that have limited injectable GLP-1 therapies despite their proven effectiveness.
Novo Nordisk edges closer to EU nod for MASH drug
The European Medicines Agency recommended semaglutide for metabolic dysfunction-associated steatohepatitis (MASH), positioning it as the first GLP-1–based treatment for this silent liver disease in the EU. Approval would represent a significant shift from managing late-stage liver complications to intervening earlier in a metabolic disease that accelerates aging and reduces healthspan.
Two Polyunsaturated Lipids Demonstrate Senolytic Activity
Two conjugated polyunsaturated fatty acids, α-eleostearic acid and its methyl ester, demonstrated senolytic activity in cell cultures and mouse models across multiple tissues without systemic toxicity. The structural features of these compounds—particularly conjugation patterns and double-bond configuration—correlate with their ability to eliminate senescent cells, which accumulate with age and drive inflammatory cascades linked to chronic disease.
Vitamin K2 Extends Lifespan by Alleviating Mitochondrial Stress via the JNK‐1/SIR‐2.1/DAF‐16 Signaling Axis in Caenorhabditis elegans
Vitamin K2 at optimal concentrations (5 μM) extends lifespan in C. elegans by activating a signaling pathway that protects mitochondria from oxidative stress, maintains ATP production, and enhances cellular stress resistance. This mechanism operates through preservation of mitochondrial function and reduction of reactive oxygen species accumulation.
Dual GLP1-Glucagon Agonist Sustains 9% Weight Loss Without Plateau
DA-1726, a once-weekly dual GLP1R/GCGR agonist, produced 9.1% mean body weight loss and 3.4 kg/m² BMI reduction over 54 days in Phase 1 trials with a favorable safety profile. This represents a meaningful advancement in pharmacological weight management, particularly given the rapid timeframe and absence of weight-loss plateau through eight weeks.
GLP-1 drugs fail to slow cognitive decline in Alzheimer’s disease
Recent evidence indicates GLP-1 receptor agonists do not slow cognitive decline in established Alzheimer's disease, despite theoretical mechanistic rationale and their known metabolic benefits. This finding redirects focus toward earlier intervention windows and prevention strategies rather than disease reversal in advanced stages.
GLP-1 drugs hint at protection against neurodegeneration
GLP-1 receptor agonists show mechanistic promise against neurodegeneration through multiple pathways—improved mitochondrial function, enhanced cellular cleanup, and reduced inflammation—but human evidence remains preliminary, with mixed cognitive outcomes in early trials and inconsistent results across disease types.